Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | TK2 | O00142 | 3/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.42 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084982 | 0.91 | PYGM (0.68) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3080113 | 0.91 | PYGM (0.68) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3071097 | 0.85 | PYGM (0.55) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3072346 | 0.83 | PYGM (0.55) | PYGMTK2P2RY2DNPH1 | |
| SCHEMBL4181065 | 0.79 | TK2 (0.67) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4181063 | 0.79 | TK2 (0.67) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4181060 | 0.79 | TK2 (0.67) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4952193 | 0.79 | TK2 (0.85) | PYGMTK2 | |
| SCHEMBL8775826 | 0.79 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9465927 | 0.79 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284741-B1 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1964569-A2 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections | Pharmasset, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7094770-B2 | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections | PHARMASSET, LTD. (BB) | 2006-08-22 | — | — | US | disclosed |
| EP-1284741-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | Pharmasset, Ltd. (BB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | PYGM 632/4885TK2 54/4885SLC28A1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.